{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-278325","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2023-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.981099+00:00","generated_at":"2026-06-08T01:15:07.918517+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Homology Medicines to merge with Q32 Bio; Q32 shareholders to own 75%, combined company targets autoimmune pipeline","bullets":["Homology issues stock to Q32 holders; pre-merger Homology shareholders own ~25%, Q32 ~75%; CVR issued for legacy asset proceeds.","Concurrent $42M private placement (OrbiMed, Atlas, Bristol Myers Squibb, etc.) to fund Phase 2 trials of bempikibart and ADX-097.","Combined company expects ~$115M cash at close, runway to mid-2026; Homology discontinues R&D, including PKU gene therapy HMI-103.","Q32 reacquired worldwide rights to bempikibart (anti-IL-7Rα) from Amgen; Phase 2 topline data for atopic dermatitis & alopecia areata in 2H 2024.","ADX-097 (tissue-targeted complement inhibitor) Phase 1 safety positive; Phase 2 basket trial start expected with proof-of-concept data by year-end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-278325","json":"https://secwatch.observer/filing/0001193125-23-278325.json","markdown":"https://secwatch.observer/filing/0001193125-23-278325.md","text":"https://secwatch.observer/filing/0001193125-23-278325.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312523278325/0001193125-23-278325-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312523278325/d350321d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T01:15:07.918517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}